Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
On Oct. 16, 2026, NDRA is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
Endra Life Sciences Inc. is a small-cap company with a market capitalization of $7M. It ranks number 26 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast.
For NDRA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 30.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 22.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NDRA included.
Follow NDRA free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
| Metric | NDRA | Rank |
|---|---|---|
| Market Cap | $7M | 26/30 |
| EPS | $-8.87 | – |
| Metric | NDRA | Rank |
|---|---|---|
| D/E Ratio | 0.26x | 20/25 |
| Financial Leverage | 1.26x | 21/25 |
| Interest Coverage | -180.4x | 25/30 |
| Metric | NDRA | Rank |
|---|---|---|
| Operating Cash Flow | -$5M | 18/30 |
| Metric | NDRA | Rank |
|---|---|---|
| Operating Income | -$8M | 20/30 |
| R&D Expense | $2M | 19/28 |
| SG&A Expense | $9M | 21/26 |
| Metric | NDRA | Rank |
|---|---|---|
| Shares Outstanding | 2M | – |
| Total Liabilities | $2M |
Companies classified under the same SEC industry code as Endra Life Sciences Inc. (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $327M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| VANI Vivani Medical, Inc. | ▶ | $104M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $75M |
| OM Outset Medical, Inc. | ▲ | $74M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| POSC Positron Corp | ▲ | $53M |
| VASO Vaso Corp | ▲ | $51M |
| POCI Precision Optics Corporation, Inc. | ▲ | $48M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| ITOC Itonic Holdings Ltd | ▶ | $28M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| ADMT Adm Tronics Unlimited, Inc. | ▼ | $3M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| NUWE Nuwellis, Inc. | ▶ | $2M |
| ESMC Escalon Medical Corp | ▶ | $1M |
| HCIL Hongchang International Co., Ltd | ▶ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Good day, ladies and gentlemen and welcome to the ENDRA Life Sciences Fourth Quarter 2019 Financial Results Conference Call. All lines have been placed on listen-only mode and the floor will be open ...
ANN ARBOR, Mich., May 14, 2026--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On Oct. 16, 2026, NDRA is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
For NDRA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 30.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 22.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Endra Life Sciences Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
32 issuers in our coverage, NDRA included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.